<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633344</url>
  </required_header>
  <id_info>
    <org_study_id>CRID CODE-7-180</org_study_id>
    <nct_id>NCT03633344</nct_id>
  </id_info>
  <brief_title>Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form in Patients With Acute Diarrhea</brief_title>
  <official_title>Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form (Carbowhite) in Patients With Acute Diarrhea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omnifarma Kiev LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omnifarma Kiev LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the antidiarrheal efficacy of colloidal silicon
      dioxide in tablet dosage form (Carbowhite) in patients with acute diarrhea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Diarrhea is a medical condition characterized by frequent stool, more than 3
      times (and more than 5-7 times in newborns) within the last 24 hours, and/or loose stool. The
      fecal matter is liquid, its daily mass exceeds 200 g per day, and water content reaches 95%.

      Objectives: To demonstrate the antidiarrheal efficacy of colloidal silicon dioxide in tablet
      dosage form (Carbowhite) in patients with acute diarrhea.

      Methods: A randomized clinical trial, double-blind, placebo-controlled, multi-center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2016</start_date>
  <completion_date type="Actual">October 7, 2016</completion_date>
  <primary_completion_date type="Actual">October 7, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Frequency of Defecation to 3 Times Per Day</measure>
    <time_frame>From randomisation up to 5 days</time_frame>
    <description>Percent of patients administered the investigational production who achieved the efficacy endpoint (reduction in frequency of defecation to 3 times per day, absence of loose stool) on Day 5 or earlier</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance Rate</measure>
    <time_frame>From randomisation up to 5 days</time_frame>
    <description>Percent of patients administered the investigational production who discontinued the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment</measure>
    <time_frame>From randomisation up to 5 days</time_frame>
    <description>Mean duration of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of Used Medication</measure>
    <time_frame>From randomisation up to 5 days</time_frame>
    <description>Mean quantity of tablets per treatment course</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Diarrhoea;Acute</condition>
  <arm_group>
    <arm_group_label>Carbowhite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbowhite placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbowhite</intervention_name>
    <arm_group_label>Carbowhite</arm_group_label>
    <other_name>Colloidal Silicon Dioxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbowhite placebo</intervention_name>
    <arm_group_label>Carbowhite placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed Informed Consent Form for patient's study participation

          -  male and female patients at the ages from 18 to 55 years

          -  acute diarrhea (more than three episodes of liquid stool a day) within 48 hours or
             less in patients with usually normal stool

          -  body temperature of ≤ 38 °C

          -  patient's ability to adequately cooperate in the process of study

        Exclusion Criteria:

          -  aged of &lt;18 or &gt;55 years;

          -  blood or pus in stool;

          -  body temperature of &gt;38 °C;

          -  episodes of acute diarrhea for the last 30 days;

          -  administration of antidiarrheal products for the last 24 hours;

          -  salmonellosis (Salmonella of any serotype different from S. typhi and S. paratyphi;
             ICD-10: A02.0), dysentery (Shigella dysenteriae, Shigella flexneri, Shigella boydii;
             ICD-10: A03.0-A03.3), colibacillosis (Escherichia coli; ICD-10: A04.0-A04.4) which
             require administration of antimicrobial products;

          -  pregnancy, lactation;

          -  concomitant decompensated diseases or acute conditions which, according to an
             investigator, may affect study results

          -  alcoholism and drug abuse;

          -  participation in any other clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oleg Kurchenko</last_name>
    <role>Study Director</role>
    <affiliation>Omnifarma Kyiv LLC</affiliation>
  </overall_official>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <results_first_submitted>August 29, 2018</results_first_submitted>
  <results_first_submitted_qc>March 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2019</results_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diarrhoea</keyword>
  <keyword>Carbowhite</keyword>
  <keyword>Colloidal silicon dioxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silicon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 8, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03633344/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In the study recruited 145 patients. One (1) of the patients dropped out of the study before being randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Carbowhite</title>
          <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite</description>
        </group>
        <group group_id="P2">
          <title>Carbowhite Placebo</title>
          <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carbowhite</title>
          <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite</description>
        </group>
        <group group_id="B2">
          <title>Carbowhite Placebo</title>
          <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" lower_limit="22.9" upper_limit="35.0"/>
                    <measurement group_id="B2" value="34.8" lower_limit="23.9" upper_limit="47.6"/>
                    <measurement group_id="B3" value="31.5" lower_limit="23.5" upper_limit="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Frequency of Defecation to 3 Times Per Day</title>
        <description>Percent of patients administered the investigational production who achieved the efficacy endpoint (reduction in frequency of defecation to 3 times per day, absence of loose stool) on Day 5 or earlier</description>
        <time_frame>From randomisation up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbowhite</title>
            <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite</description>
          </group>
          <group group_id="O2">
            <title>Carbowhite Placebo</title>
            <description>3 tablets as a single dose (210 mg х 3 = 630 mg) t.i.d. (630 mg х 3 = 1,890 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Frequency of Defecation to 3 Times Per Day</title>
          <description>Percent of patients administered the investigational production who achieved the efficacy endpoint (reduction in frequency of defecation to 3 times per day, absence of loose stool) on Day 5 or earlier</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance Rate</title>
        <description>Percent of patients administered the investigational production who discontinued the study</description>
        <time_frame>From randomisation up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbowhite</title>
            <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite</description>
          </group>
          <group group_id="O2">
            <title>Carbowhite Placebo</title>
            <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance Rate</title>
          <description>Percent of patients administered the investigational production who discontinued the study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Treatment</title>
        <description>Mean duration of treatment</description>
        <time_frame>From randomisation up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbowhite</title>
            <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite</description>
          </group>
          <group group_id="O2">
            <title>Carbowhite Placebo</title>
            <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Treatment</title>
          <description>Mean duration of treatment</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.6" upper_limit="1.9"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.3" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantity of Used Medication</title>
        <description>Mean quantity of tablets per treatment course</description>
        <time_frame>From randomisation up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbowhite</title>
            <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite</description>
          </group>
          <group group_id="O2">
            <title>Carbowhite Placebo</title>
            <description>3 tablets as a single dose (210mg х 3 = 630 mg) t.i.d. (630 mg х 3 = 1,890 mg);</description>
          </group>
        </group_list>
        <measure>
          <title>Quantity of Used Medication</title>
          <description>Mean quantity of tablets per treatment course</description>
          <units>tablets</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O2" value="36" lower_limit="24" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Carbowhite</title>
          <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite</description>
        </group>
        <group group_id="E2">
          <title>Carbowhite Placebo</title>
          <description>3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
Carbowhite placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Oleg Kurchenko</name_or_title>
      <organization>Omnifarma Kyiv LLC</organization>
      <phone>+380503319653</phone>
      <email>Kurchenko@omnifarma.kiev.ua</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

